Expected Changes to the Vendor Landscape in 2018

Over the last several decades, CROs have become heavily involved in the conduct of clinical trials. But relationships between sponsors and CROs are not seamless, and outsourcing to a CRO ends up causing a slew of complications for the sponsor.
Read More

Looking back on Halloran's 20 years

Early in my career, I worked as a pediatric nurse in an intensive care unit. As you can imagine, it was often difficult work.  I saw families desperate for treatments, and all too often, their medical teams had to deliver bad news.
Read More

Q&A: 2018 trends with Pharma IQ

Predictive analytics will help keep clinical trials in the world of actual data rather than succumbing to “alternative data.”  No longer will we be stuck estimating enrollment rates, trial costs or other simple outputs of multi-factorial processes.  
Read More

Addressing the rapidly changing clinical landscape

The Cures Act is part of a broader effort by FDA to improve the regulatory process and speed treatments to those in need.  Dr. Gottlieb published a blog post affirming FDA’s commitment to hiring staff and meeting the goals of HHS Secretary’s Reimagine FDA directive.
Read More